IGF-1 LR3 (insulin-like growth factor-1 long arginine 3) is a synthetic, modified construct of insulin-like growth factor-1. Because IGF-1 LR3 does not bind to IGF-1 binding proteins very well, it remains active up to 120 times longer than standard IGF-1. This results in improved half-life for the peptide and thus increased activity. IGF-1 LR3 enhances cell division and growth, boosts fat metabolism, and increases muscle repair and hypertrophy by inhibiting myostatin. Recent research suggests that IGF-1 LR3 may also be useful in improving lactation among mothers with young offspring.
Extended Half-Life IGF-1 Analog for Growth Studies
IGF-1 LR3 (Long Arg3 IGF-1) is a modified version of insulin-like growth factor-1 with enhanced potency and extended half-life. This research peptide enables prolonged studies of growth factor pathways, cellular proliferation, and metabolic regulation mechanisms.
Research Applications:
- Growth factor receptor studies
- Cellular proliferation research
- Metabolic pathway analysis
- Protein synthesis mechanism studies
- Cell survival pathway investigations
Specifications:
- Modified IGF-1 with 13 additional amino acids
- Extended biological half-life
- Enhanced receptor binding affinity
- Research-grade purity standards
For in-vitro research purposes only.
IGF-1 LR3 1mg - Long-Acting Insulin-Like Growth Factor
- Typical dosages can range, but commonly it’s 2mg per vial, which can be reconstituted with sterile water.
- The peptide is typically administered via subcutaneous injection.
- The dosing regimen often involves one injection per week, as it has a prolonged half-life (due to the DAC component).
- As with any peptide, there could be risks, such as injection site reactions, water retention, or possible changes in insulin sensitivity.
- It’s important to monitor health regularly and consult with a healthcare provider, especially if using for long-term purposes.
